#generics

Teva’s new version of TDF and emtricitabine doesn’t offer much of a price break, but that could come next spring.

A low-cost generic version of Truvada as PrEP will hit the market September 30.

Fact-checkers and HIV advocates break down the president’s State of the Union boasts.

A new lawsuit accuses the imprisoned hedge funder of blocking generic rivals of an AIDS-related drug.

“This is excellent news for all children living with HIV.”

The FDA has found a probable cancer-causing contaminant in generic drugs shipped from abroad––most recently, Zantac (ranitidine).

At the center of the lawsuit is Teva Pharmaceutical, slated to sell a generic version of the HIV prevention pill PrEP next year.

The head of the Food and Drug Administration cited a long commute and time away from family as reasons to step down.

U.S. activists unveil a national action plan to #BreakThePatent. It points out that taxpayers funded the research behind Truvada as PrEP.

Stocks of drug companies are rising—and that’s not a good sign for consumers.

The FDA commissioner wants drugmakers to “end the shenanigans.”

However, Gilead Sciences, the brand-name manufacturer of Truvada, insists a generic version “will not be immediately available.”

Scott Gottlieb has said he wants lower costs and faster drug approvals.

New HCV treatment boasts over 90 percent cure rates, costs $84,000 for in the United States.

The Irish pharmaceutical company Actavis has agreed to buy out rival New York City-based Forest Laboratories.

Bill proposed as a way to close gaps in care and get cheaper meds to the people who need them.